Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2018 Feb 17

PMID 29449336

Citations 10

Authors

Nigel Mackman

Henri M H Spronk

George A Stouffer

Hugo Ten Cate

Affiliations

Soon will be listed here.

Citing Articles

Green biosynthetic silver nanoparticles from as multifunctional hemostatic agents: Combining hemostasis, antibacterial, and anti-inflammatory properties for effective wound healing.

Li Y, Tan Y, Zhao H, Chen S, Nilghaz A, Cao R Mater Today Bio. 2025; 31:101468.

PMID: 39906203 PMC: 11791296. DOI: 10.1016/j.mtbio.2025.101468.

Myocardial infarction following held antiplatelet therapy for lumbar radiofrequency neurotomy: A letter to the editor.

Galbraith W, Khan S, Gardner J, Schneider B Interv Pain Med. 2024; 2(1):100171.

PMID: 39239596 PMC: 11373001. DOI: 10.1016/j.inpm.2022.100171.

Cardiovascular Tissue Engineering Models for Atherosclerosis Treatment Development.

Tscheuschner L, Tzafriri A Bioengineering (Basel). 2023; 10(12).

PMID: 38135964 PMC: 10740643. DOI: 10.3390/bioengineering10121373.

Plant-Derived Compounds and Extracts as Modulators of Plasmin Activity-A Review.

Kolodziejczyk-Czepas J, Czepas J Molecules. 2023; 28(4).

PMID: 36838662 PMC: 9965408. DOI: 10.3390/molecules28041677.

Platelet-Neutrophil Crosstalk in Thrombosis.

Mereweather L, Constantinescu-Bercu A, Crawley J, Salles-Crawley I Int J Mol Sci. 2023; 24(2).

PMID: 36674781 PMC: 9861587. DOI: 10.3390/ijms24021266.

References

Scirica B, Bonaca M, Braunwald E, De Ferrari G, Isaza D, Lewis B . Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012; 380(9850):1317-24. DOI: 10.1016/S0140-6736(12)61269-0. View

Bhatt D, Flather M, Hacke W, Berger P, Black H, Boden W . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49(19):1982-8. DOI: 10.1016/j.jacc.2007.03.025. View

Roe M, Armstrong P, Fox K, White H, Prabhakaran D, Goodman S . Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367(14):1297-309. DOI: 10.1056/NEJMoa1205512. View

Cui J, OShea K, Purkayastha A, Saunders T, Ginsburg D . Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996; 384(6604):66-8. DOI: 10.1038/384066a0. View

Lee I, Kratz M, Schirmer S, Baumhakel M, Bohm M . The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012; 343(2):253-7. DOI: 10.1124/jpet.112.194837. View

Li D, Wang Y, Zhang L, Luo X, Li J, Chen X . Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012; 32(8):e81-9. DOI: 10.1161/ATVBAHA.111.239095. View

Loeffen R, Spronk H, ten Cate H . The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012; 10(7):1207-16. DOI: 10.1111/j.1538-7836.2012.04782.x. View

Pingel S, Tiyerili V, Mueller J, Werner N, Nickenig G, Mueller C . Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci. 2014; 10(1):154-60. PMC: 3953984. DOI: 10.5114/aoms.2014.40742. View

Bonaca M, Bhatt D, Steg P, Storey R, Cohen M, Im K . Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2015; 37(14):1133-42. DOI: 10.1093/eurheartj/ehv531. View

10.

Sparkenbaugh E, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel R, Monroe D . Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014; 123(11):1747-56. PMC: 3954055. DOI: 10.1182/blood-2013-08-523936. View

11.

Bhatt D . Identification of and management approaches for the high-risk patient. Am J Cardiol. 2006; 98(12A):22Q-29Q. DOI: 10.1016/j.amjcard.2006.09.021. View

12.

Chackalamannil S, Wang Y, Greenlee W, Hu Z, Xia Y, Ahn H . Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51(11):3061-4. DOI: 10.1021/jm800180e. View

13.

Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D . Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2017; 11(2):181-191. PMC: 5775044. DOI: 10.1016/j.jcin.2017.07.022. View

14.

Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16):1706-17. DOI: 10.1056/NEJMoa060989. View

15.

Burger P, Wagner D . Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2002; 101(7):2661-6. DOI: 10.1182/blood-2002-07-2209. View

16.

Bonaca M, Scirica B, Creager M, Olin J, Bounameaux H, Dellborg M . Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013; 127(14):1522-9, 1529e1-6. DOI: 10.1161/CIRCULATIONAHA.112.000679. View

17.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

18.

Zuo P, Zuo Z, Zheng Y, Wang X, Zhou Q, Chen L . Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice. Front Pharmacol. 2017; 8:647. PMC: 5603739. DOI: 10.3389/fphar.2017.00647. View

19.

Tendera M, Aboyans V, Bartelink M, Baumgartner I, Clement D, Collet J . ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and.... Eur Heart J. 2011; 32(22):2851-906. DOI: 10.1093/eurheartj/ehr211. View

20.

Sun W, Witte D, Degen J, Colbert M, Burkart M, Holmback K . Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A. 1998; 95(13):7597-602. PMC: 22695. DOI: 10.1073/pnas.95.13.7597. View